Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Needs To Show Xgeva Does More Than Delay Bone Metastases, ODAC Says

Executive Summary

Measurement of a downstream endpoint, such as delay in skeletal-related events, could have been better than radiographic scans to assess efficacy of denosumab in delaying bone metastases in high-risk castration-resistant prostate cancer patients, several ODAC members contend.

You may also be interested in...



NCI Expert Drafts Roadmap For Metastasis-Prevention Trials

National Cancer Institute’s Patricia Steeg highlights “huge barrier” for developing drugs that prevent breast cancer metastases but don’t work on traditional tumor shrinkage endpoints. She urges new guidance from FDA and input from the oncology community to pave the way for promising drugs.

Xgeva Rejection Shows What’s Needed For Non-Metastatic CRPC Approvals

As expected, FDA rejected the new indication for Amgen’s bone drug Xgeva in prevention of bone metastases. But the door is still open for other therapies for castration resistant prostate cancer to target earlier stages of disease.

A Picture is Worth a Thousand Words

One FDA advisory committee urges a sponsor to get graphic in its REMS for a weight loss drug. Another committee rejects an expanded label after FDA shows a picture of the risk in its presentation.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel